Hepatocellular carcinoma
Conditions
Interventions
Intervention group:Celecoxib fever after hepatic artery embolization for Celecoxib was used for fever after hepatic artery embolization with hepatocellular carcinoma
control group:none
Sponsors
Lishui Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Aged from 18 to 80 years; (2) Diagnosed with HCC based on the criteria established by the American Association for the Study of Liver Diseases (AASLD); (3) Inoperable HCC; the nodule size is greater than 3 cm; (4) Without radiotherapy, chemotherapy and molecular targeted therapy in a month; (5) Main portal vein without clogging, or occlusion but the formation of collateral vessels; (6) had a Karnofsky Performance Status (KPS) score =70; (7) stage A or B HCC according to the Barcelona Clinic Liver Cancer (BCLC) staging classification.
Exclusion criteria
Exclusion criteria: (1) a history of serious allergic reactions to medicines, pregnancy or breastfeeding women; (2) heart failure, severe hepatic and renal dysfunction; (3) hypersensitivity to celecoxib; (4) white blood cell counts (WBCs)<4.0×10^9/L, platelets <50×10^9/L; (5) Coagulation defects; (6) Intrahepatic arteriovenous fistula; (7) Obvious pleural effusion and ascites; (8) gastrointestinal hemorrhage in the last 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life;Safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| post-operative complication;progression free survival;Immune status; | — |
Countries
China
Contacts
Public ContactJiansong Ji
Lishui Central Hospital
Outcome results
None listed